Testimony

;

Gilead Sciences v Maritain Health reply to opposition to file an amicus brief

Jan 9, 2026

Five patient groups, led by HIV+Hep, submitted an amicus brief in Gilead Sciences v Meritain Health to describe the harm of employers forcing patients to use alternative funding programs and illegally imported prescription drugs. Meritain Health et al opposed the admission of our amicus brief, and we replied with this brief that Meritain’s opposition shows a lack of concern for the patients for whom we advocate. The Court ruled that the brief be accepted.

read more

Support for PrEP DC Act of 2025 (B26-0159)

Oct 30, 2025

Today we testify in support of the PrEP DC Act of 2025 (B26-0159) introduced by Councilmember Zachary Parker and co-introduced by eight other councilmembers. As the District continues to make progress in reducing the number of HIV infections, it must do everything possible in its power to ensure people who have a reason to protect themselves against HIV have access to all available prevention tools. That includes PrEP, which are incredible drugs that prevent HIV if people can access and afford them.

read more

Amicus brief in support of Iowa’s copay assistance law

Oct 8, 2025

HIV+Hep filed an amicus brief in support of Iowa’s PBM reform law that requires copay assistance to count for Rx’s not only in ACA plans but for the first time, employer plans. PBMs contend it is unlawful under ERISA. In our brief we explain to the US 8th Circuit Court of Appeals why it is not.

read more

Testimony to Massachusetts Joint Committee on Financial Services on Bills to Address Barriers to HIV Medication

Sep 17, 2025

On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of H.1245/S.717: An Act to address barriers to HIV prevention medication. PrEP is a key component of both Massachusetts and federal strategies to end the HIV epidemic. But thirteen years after the introduction of PrEP, only a third of those who would benefit from PrEP are on it, with stark racial, ethnic, and gender disparities in uptake.

read more

Senate testimony on FY26 appropriations for HIV and hepatitis

Jun 13, 2025

As a nation, we are able to advance efforts to end the HIV and viral hepatitis epidemics. We possess proven prevention tools, including pre-exposure prophylaxis medication (PrEP), and effective treatments. We urge you to continue your historically strong commitment and leverage this pivotal moment to support the nation’s public health by comprehensively addressing these chronic diseases. Increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis and allow us to continue to hold the promise of ending these epidemics.

read more

Search

Categories

Tags

340B ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest